Pfizer CEO Albert Bourla said his company won't apply for an emergency use authorization (EUA) for a potential COVID-19 vaccine until at least the third week of November. The announcement virtually eliminates any chances that a vaccine will be ready before the Nov. 3 election.
- Bourla said his company would know the effectiveness of the vaccine by the end of October and be able to determine if it's safe by the third week of November.
- Pfizer is working with German company BioNTech and is conducting trials on 44,000 volunteers. Its current candidate requires two doses, one month apart.
- If U.S health regulators were to approve the vaccine, it could start being distributed in December. The FDA has said it requires at least two months of safety data before it will approve an EUA.
- Pfizer is one of several drugmakers whose vaccine candidate is in Phase 3 trials, including Johnson & Johnson and Moderna. Johnson & Johnson stopped its trials earlier this week after a patient developed an unexplained illness.